DMTX Dimension Therapeutics, Inc.

2.00
+0  (3%)
Previous Close 1.95
Open 1.95
Price To book 0.81
Market Cap 50.09M
Shares 25,043,000
Volume 253,544
Short Ratio 1.13
Av. Daily Volume 179,046

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiated December 2016. Initial data due 2H 2017.
DTX101
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2 initial data released January 31, 2017.
DTX101
hemophilia B

Latest News

  1. Edited Transcript of DMTX earnings conference call or presentation 9-Mar-17 1:30pm GMT
  2. Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  3. Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  4. DIMENSION THERAPEUTICS, INC. Financials
  5. Can The Uptrend Continue for Dimension Therapeutics (DMTX)?
  6. DIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  7. DIMENSION THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
  8. Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
  9. Q4 2016 Dimension Therapeutics Inc Earnings Release - Before Market Open
  10. Dimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call
  11. Lifshitz & Miller LLP Announces Investigation of BT Group plc, Celadon Group, Inc., Community Health Systems, Inc., Dimension Therapeutics, Inc., Home Capital Group Inc., Lifevantage Corporation, OvaScience, Inc. and Under Armour, Inc.
  12. Newman Ferrara LLP Announces Corporate Governance Investigation of Dimension Therapeutics Inc.
  13. Cerner's EHR Platform to Enhance Health Care at San Juan NGO
  14. Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
  15. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dimension Therapeutics, Inc.
  16. Dimension Therapeutics downgraded by Cantor Fitzgerald
  17. DIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events
  18. Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
  19. vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher
  20. DIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers